
TY  - JOUR
TI  - Poster Presentations
JO  - Acta Physiologica
JA  - Acta Physiol
VL  - 216
IS  - S707
SN  - 1748-1708
UR  - https://doi.org/10.1111/apha.12672
DO  - doi:10.1111/apha.12672
SP  - 85
EP  - 223
PY  - 2016
ER  - 

TY  - JOUR
TI  - THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
JO  - Australian and New Zealand Journal of Medicine
VL  - 30
IS  - 4
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.2000.tb02071.x
DO  - doi:10.1111/j.1445-5994.2000.tb02071.x
SP  - 523
EP  - 549
PY  - 2000
ER  - 

AU  - Shah, Nisarg J.
AU  - Hsu, Bryan B.
AU  - Dreaden, Erik C.
AU  - Hammond, Paula T.
C7  - pp. 131-170
TI  - Engineering Layer-by-Layer Thin Films for Multiscale and Multidrug Delivery Applications
SN  - 9783527335893
UR  - https://doi.org/10.1002/9783527675869.ch7
DO  - doi:10.1002/9783527675869.ch7
SP  - 131-170
KW  - biologics
KW  - controlled release systems
KW  - layer-by-layer (LbL) multilayer delivery systems
KW  - nanomedicine
KW  - small molecules
KW  - targeted systemic delivery
KW  - tissue regeneration
KW  - vaccination
KW  - wound healing
PY  - 2000
AB  - Summary This chapter discusses some of the approaches and recent developments in layer-by-layer (LbL) multilayer delivery systems. It first addresses the range of mechanisms that can be employed to create controlled release systems with different characteristic rates of release, as well as the means of introducing different types of molecules into the LbL film structure, including the particular challenge of release of small molecules with control. The chapter then addresses in more detail the incorporation of biologics into LbL release systems for the purpose of stimulating or manipulating cellular response in vivo, which can be used to address tissue regeneration, vaccination, and wound healing. Finally, it discusses the adaptation of these principles to nanomedicine and provides examples of how these concepts and principles can be adapted to enable the manipulation of nanoparticles for targeted systemic delivery.
ER  - 

TY  - JOUR
TI  - SYSTEMIC LUPUS ERYTHEMATOSUS – AETIOLOGY AND PATHOGENESIS/ANIMAL MODELS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_29.x
DO  - doi:10.1111/j.1479-8077.2006.00199_29.x
SP  - A247
EP  - A253
PY  - 2006
ER  - 

TY  - JOUR
TI  - CARTILAGE IN BONE BIOLOGY AND PATHOPHYSIOLOGY
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_5.x
DO  - doi:10.1111/j.1479-8077.2006.00199_5.x
SP  - A33
EP  - A39
PY  - 2006
ER  - 

TY  - JOUR
TI  - Fourth Annual Meeting of the European Tissue Repair Society Academic Centre—John Radcliffe Hospital Oxford, England, August 25–28, 1994
JO  - Wound Repair and Regeneration
JA  - Wound Repair and Regeneration
VL  - 2
IS  - 3
SN  - 9783527335893
UR  - https://doi.org/10.1046/j.1524-475X.1994.20310.x
DO  - doi:10.1046/j.1524-475X.1994.20310.x
SP  - 194
EP  - 194
PY  - 1994
ER  - 

TY  - JOUR
TI  - Short Submitted Peer Reviewed Abstracts
JO  - Oral Diseases
VL  - 16
IS  - 6
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1601-0825.2010.01743.x
DO  - doi:10.1111/j.1601-0825.2010.01743.x
SP  - 516
EP  - 572
PY  - 2010
ER  - 

TY  - JOUR
AU  - Sánchez, Mikel
AU  - Anitua, E.
AU  - Delgado, D.
AU  - Prado, R.
AU  - Sánchez, P.
AU  - Fiz, N.
AU  - Guadilla, J.
AU  - Azofra, J.
AU  - Pompei, O.
AU  - Orive, G.
AU  - Ortega, M.
AU  - Yoshioka, T.
AU  - Padilla, S.
C8  - TERM-15-0073.R1
TI  - Ultrasound-guided plasma rich in growth factors injections and scaffolds hasten motor nerve functional recovery in an ovine model of nerve crush injury
JO  - Journal of Tissue Engineering and Regenerative Medicine
JA  - J Tissue Eng Regen Med
VL  - 11
IS  - 5
SN  - 9783527335893
UR  - https://doi.org/10.1002/term.2079
DO  - doi:10.1002/term.2079
SP  - 1619
EP  - 1629
KW  - PRGF
KW  - platelet-rich plasma
KW  - growth factors
KW  - peripheral nerve injury
KW  - muscle atrophy
KW  - fibrin
KW  - scaffold
KW  - compound muscle action potential
PY  - 2017
AB  - Abstract In the present study we evaluated the motor recovery process of peripheral nerve injury (PNI), based on electrophysiological and histomorphometric criteria, after treatment with plasma rich in growth factors (PRGF) injections and scaffolds in an ovine model. Three groups of sheep underwent a nerve crush lesion: the first group (n?=?3) was left to recover spontaneously (SR); the second group was administered saline injections (SI; n?=?5) and a third group (n?=?6) received PRGF injections and scaffolds immediately after the crush injury. At post-intervention week 8, 70% of sheep in the PRGF group were CMAP-positive, with no electrophysiological response in the rest of the groups. Histomorphometric analysis 12?weeks after the surgical intervention revealed that the average axonal density of the SR (1184?±?864 axons/µm2) and SI (3109?±?2450 axons/µm2) groups was significantly inferior to the control (8427?±?2433 axons/µm2) and also inferior to the PRGF group (5276?±?4148 axons/µm2), showing no significant differences between the control and PRGF groups. The axonal size of the SR and SI groups was significantly smaller compared with the control group (18?±?4?µm2), whereas the axonal size of the PRGF group (6?±?5?µm2) did not show statistical differences from the control. Morphometry of the target muscles indicated that the PRGF group had the lowest percentage volume reduction 12?weeks after the crush injury. The PRGF group had larger muscle fibre areas than the SI and SR groups, although the differences did not reach statistical significance. Overall, these data suggest that the PRGF injections and scaffolds hastened functional axon recovery and dampened atrophy of the target muscles in an ovine model. Copyright ? 2015 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Scientific Section
JO  - Transfusion
VL  - 49
IS  - s3
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1537-2995.2009.02366.x
DO  - doi:10.1111/j.1537-2995.2009.02366.x
SP  - 1A
EP  - 305A
PY  - 2009
ER  - 

TY  - JOUR
TI  - MYOPATHIES AND SOFT TISSUE RHEUMATISM INCLUDING FIBROMYALGIA
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_17.x
DO  - doi:10.1111/j.1479-8077.2006.00199_17.x
SP  - A99
EP  - A101
PY  - 2006
ER  - 

TY  - JOUR
TI  - RHEUMATOID ARTHRITIS – AETIOLOGY AND PATHOGENESIS/ANIMAL MODEL
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_25.x
DO  - doi:10.1111/j.1479-8077.2006.00199_25.x
SP  - A211
EP  - A225
PY  - 2006
ER  - 

TY  - JOUR
TI  - Brief Orals
JO  - Transplant International
JA  - Transpl Int
VL  - 30
IS  - S2
SN  - 9783527335893
UR  - https://doi.org/10.1111/tri.13050
DO  - doi:10.1111/tri.13050
SP  - 165
EP  - 346
PY  - 2017
ER  - 

TY  - JOUR
TI  - Plenary III: Dravet Syndrome 11:00 a.m.-12:30 p.m.
JO  - Epilepsia
VL  - 49
IS  - s7
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1528-1167.2008.01871_21.x
DO  - doi:10.1111/j.1528-1167.2008.01871_21.x
SP  - 498
EP  - 498
PY  - 2008
AB  - Ingrid E. Scheffer ? Austin Health, University of Melbourne, West Heidelberg, VIC, Australia Summary: Until now, the discovery of genes for monogenic epilepsies has not had significant clinical impact. With the finding that around 70% of children with Dravet syndrome, or severe myoclonic epilepsy of infancy, have mutations of SCN1A, epilepsy genetics has moved into the clinical domain. Recognition of Dravet syndrome requires an understanding of a complex phenotype including seizure onset in the first year of life, multiple seizure types, developmental slowing, neurological deficits and EEG features. Genotype-phenotype correlation has led to the identification of novel SCN1A epileptic encephalopathies such as severe infantile multifocal epilepsy that should also be considered for mutational analysis. Translational research with the development of animal models of SCN1A mutations has led to significant insights into the neurobiology of Dravet syndrome. SCN1A knockout mice recapitulate the human disorder with seizures and ataxia leading to early death in heterozygotes. Mice show strain-specific penetrance of disease reflecting the genetic background effects that modify phenotypic severity in humans. Cellular studies show that dysfunction of the interneuron in cortex, rather than excitatory cells, underlies the phenotype. GABAergic cells are also implicated in the cerebellum with Purkinje cell dysfunction underlying ataxia. The diagnostic finding of a SCN1A mutation associated with Dravet syndrome or a related phenotype has major implications for treatment, prognostic and genetic counseling. Specific antiepileptic agents are effective in Dravet syndrome whilst others cause seizure exacerbation. Stiripentol has been shown to be effective in Dravet syndrome. Early diagnosis allows the clinician to optimise anti-epileptic therapy with the aim of improving developmental outcome.
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - APMIS
VL  - 120
IS  - s134
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1600-0463.2012.02894.x
DO  - doi:10.1111/j.1600-0463.2012.02894.x
SP  - 18
EP  - 39
PY  - 2012
ER  - 

TY  - JOUR
TI  - METABOLIC AND CRYSTAL ARTHROPATHIES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_15.x
DO  - doi:10.1111/j.1479-8077.2006.00199_15.x
SP  - A83
EP  - A90
PY  - 2006
ER  - 

TY  - JOUR
TI  - OSTEOARTHRITIS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_19.x
DO  - doi:10.1111/j.1479-8077.2006.00199_19.x
SP  - A108
EP  - A125
PY  - 2006
ER  - 

TY  - JOUR
TI  - ANTI-PHOSPHOLIPID SYNDROME
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_2.x
DO  - doi:10.1111/j.1479-8077.2006.00199_2.x
SP  - A25
EP  - A26
PY  - 2006
ER  - 

TY  - JOUR
TI  - PAEDIATRIC RHEUMATOLOGY
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_22.x
DO  - doi:10.1111/j.1479-8077.2006.00199_22.x
SP  - A159
EP  - A167
PY  - 2006
ER  - 

TY  - JOUR
TI  - RHEUMATOID ARTHRITIS – TREATMENT
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_24.x
DO  - doi:10.1111/j.1479-8077.2006.00199_24.x
SP  - A188
EP  - A210
PY  - 2006
ER  - 

TY  - JOUR
TI  - SJOGREN'S SYNDROME
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9783527335893
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_27.x
DO  - doi:10.1111/j.1479-8077.2006.00199_27.x
SP  - A230
EP  - A234
PY  - 2006
ER  - 
